Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinsonʼs disease

Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by symptoms that impact both motor and non-motor domains. Outside of motor impairments, PD patients are at risk for impulse control disorders (ICDs), which include excessively disabling impulsive and compulsive behaviors. ICD symptoms in PD (PD + ICD) can be broadly conceptualized as a synergistic interaction between dopamine agonist therapy and the many molecular and circuit-level changes intrinsic to PD. Aside from discontinuing dopamine agonist treatment, there remains a lack of consensus on how to best address ICD symptoms in PD. In this review, we explore recent advances in the molecular and neuroanatomical mechanisms underlying ICD symptoms in PD by summarizing a rapidly accumulating body of clinical and preclinical studies, with a special focus on the utility of rodent models in gaining new insights into the neurochemical basis of PD + ICD. We also discuss the relevance of these findings to the broader problem of impulsive and compulsive behaviors that impact a range of neuropsychiatric syndromes.

Download Full-text

Impulse Control Disorder in a Patient with Invasive Prolactinoma on Dopamine agonist Therapy: A Case Report

Endocrinology and Disorders ◽

10.31579/2640-1045/038 ◽

2019 ◽

Vol 3 (1) ◽

pp. 01-03

Author(s):

Pinaki Dutt

Keyword(s):

Case Report ◽

Adverse Events ◽

Dopamine Agonist ◽

Pituitary Adenomas ◽

Impulse Control ◽

Agonist Therapy ◽

Debulking Surgery ◽

Dopamine Agonist Therapy ◽

Invasive Prolactinoma

Prolactinomas constitutes a major bulk of pituitary adenomas. All symptomatic prolactinomas require dopamine agonist (DA) therapy. Impulse control disorders (ICD) or pathological behaviours are rare adverse events described with use of DA. Herein we are describing a male patient with pathological gambling and doctor shopping following use of bromocriptine and higher dose of cabergoline.The pathological behaviour disappeard after debulking surgery, reduction in cabergoline dose and several sessions of counselling. Physicians prescribing DA should be aware of this potential adverse event.This should be emphasized to the patient and family members before starting DA and physician should be inquisitive for eliciting pathological behaviour on follow up.

Download Full-text

Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(08)79039-2 ◽

2008 ◽

Vol 2008 ◽

pp. 75-76

Author(s):

S. Papapetropoulos

Keyword(s):

Parkinson Disease ◽

Dopamine Agonist ◽

Impulse Control ◽

Impulse Control Disorders

Download Full-text

Update Treatment for Prolactinoma

International Journal of Innovative Research in Medical Science ◽

10.23958/ijirms/vol03-i06/08 ◽

2018 ◽

Vol 3 (06) ◽

Author(s):

Chávez Hernández María Margarita ◽

Jiménez Báez María Valeria ◽

Armijo Medina María Fernanda ◽

Domínguez Leyva Jorge Miguel ◽

Góngora Valencia Karen Alejandra ◽

...

Keyword(s):

Dopamine Agonist ◽

Safety Profile ◽

Pituitary Tumor ◽

Common Type ◽

Treatment Modalities ◽

First Line ◽

Agonist Therapy ◽

Dopamine Agonist Therapy ◽

Gonadal Dysfunction

Prolactinomas are the most common type of functional pituitary tumor. The present manuscript is an update on the treatment modalities for prolactinomas. Effective hyperprolactinemia treatment is of great importance, due to its potential deleterious effects including infertility, gonadal dysfunction and osteoporosis. Dopamine agonist therapy is the first line of treatment for prolactinomas; recurrence of disease after cessation of the drug may occur in patients. Its safety profile remains high, allowing its use during pregnancy.

Download Full-text